Source - SMW
NetScientific said that Glycotest, a company in its investment portfolio, had  successfully completed a clinical evaluation of a liver cancer treatment.

Glycotest had begun planning for a further clinical validation study before moving into the commercial phase, aiming to make its first sale, NetScientific added.

Elsewhere, it said another of its investment companies, Vortex Biosciences, had continued to advance testing of its liver cancer treatment.

At 9:55am: (LON:NSCI) Netscientific Plc share price was 0p at 67p